The findings suggest that use of the pacing technique during CRT should be reserved for expert operators, at least for now.

A 173-patient randomized trial in HFrEF (LVEF ≤35%) with LBBB (QRS ≥130 ms) showed CSP was inferior to BiVP for a hierarchical 12‑month composite endpoint. Worse outcomes with CSP were reflected by an ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) ...

Physiologic pacing of the His-Purkinje conduction system is feasible in patients who require a permanent pacemaker following TAVR and this alternative pacing method did not interfere with ejection ...

The OmniaSecure lead gained the first U.S. approval for placement in the heart’s left bundle branch area, to help activate ...

Cardiac resynchronization therapy is a key treatment for patients with HFrEF and electrical dyssynchrony, such as LBBB. While ...

Two multicenter trials drew different conclusions about the value of conduction system relative to biventricular pacing for ...

Medtronic and Biotronik both took steps forward this week with their pacemaker hardware designed to target newly emerging ...

Medtronic snagged FDA approval for an expanded indication for its OmniaSecure defibrillation lead. Check out why this tiny ...

Medtronic announced today that it received FDA approval for an expanded indication for its OmniaSecure defibrillation lead.

Medtronic "Conduction System Pacing" Expanded Indication Now Includes Left Bundle Branch Area Pacing in Addition to His-Bundle Pacing for Patients with Slow Heart Rates Medtronic is the first and only ...